(A-G) are recognised by their serological differences, but only toxins A, B, and E cause human botulism. The toxins have no primary effect on nerve conduction or muscle function,2 but their action at the motor end plate effectively denervates the muscle and this has very important consequences. Histochemical changes in the muscle fibres develop and the difference between type I and type II fibres becomes less distinct.3 Sprouting ofnew nerve terminals and the formation of new motor end plates are seen in affected muscles. 45 The toxin appears to be irreversibly bound to the nerve terminals and antitoxin is ofno value once this binding has taken place. Recovery of function therefore depends on the formation of new motor end plates from the sprouting nerve terminals.
The clinical presentation of botulism reflects the effects of the toxin on the neuromuscular junction and autonomic synapses. Symptoms due to skeletal muscle weakness and autonomic dysfunction appear after a latent period ofusually 12-72 hours from the ingestion ofthe contaminated food. The muscles supplied by the cranial nerves weaken first, but respiratory muscle weakness usually follows. Nausea, vomiting, dry mouth, constipation, and urinary retention are common. The patient remains afebrile and conscious and sensory signs do not develop. The differential diagnosis includes the Guillain-Barre syndrome, acute poliomyelitis, myasthenia gravis, the Lambert-Eaton syndrome, tick paralysis, and chemical poisoning by, for instance, atropine and organophosphorus compounds. The diagnosis is confirmed by observing the effects ofinjection of the patient's serum into mice and by isolation of botulinum toxin from food residues.
Respiratory muscle weakness often progresses rapidly and its severity is easily underestimated. Respiratory arrest still occurs commonly before mechanical support and has been started. Blood gas alterations appear late, as in many other neuromuscular disorders, and should not be relied on. Frequent careful clinical assessment and regular measurements of vital capacity are essential. These may be supplemented by maximal inspiratory and expiratory pressure estimations if these are practicable. A rapid fall in vital capacity, a vital capacity of only a third ofthe predicted value, or a value ofaround one litre should all suggest the need for ventilatory support.6 Ventilatory support may also be needed because of failure to clear secretions and the risk of inhalation even if the vital capacity is only mildly abnormal. Aspiration pneumonia is common and it is important that the method of ventilatory support should protect the airway. Modern methods of ventilatory assistance that are valuable for domiciliary use, such as negative pressure and nasal intermittent positive pressure ventilation, are not suitable. Positive pressure ventilation via an endotracheal tube is required. A tracheostomy is usually needed, except in mild cases, since recovery ofmuscle function is usually slow. Ventilatory support is often needed for several weeks.6 Infections due to type A toxin are particularly severe and usually require a long period of ventilatory support and a long hospital stay."8 A short latent period before symptoms appear is also correlated with a more severe illness.9 Mortality during the period of ventilation used to be high, but with modern intensive care methods death should be unusual. Most deaths are now caused by failure to recognise the severity and rapidity of progression ofrespiratory muscle weakness in its early stages.
All the studies of the late results of botulism emphasise the persistence of the symptoms of muscle weakness. Fatigue, breathlessness on exertion, and diplopia are common. 6 
